Send to

Choose Destination
See comment in PubMed Commons below
Case Rep Clin Pathol. 2014 Sep;1(2):151-154.

Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus.

Author information

  • 1Department of Medicine, The University of Chicago, Chicago, IL, United States.
  • 2Department of Obstetrics/ Gynecology, The University of Chicago, Chicago, IL, United States.
  • 3Department of Radiology, The University of Chicago, Chicago, IL, United States.
  • 4Marquette General Hematology Oncology, Marquette, MI, United States.
  • 5Foundation Medicine, Cambridge, MA, United States.
  • 6Department of Neurology, University of Chicago, Chicago, IL, United States.


Anaplastic lymphoma kinase (ALK) fusion positive non-small cell lung cancer (NSCLC) is a relatively novel molecular subtype in lung cancer. ALK targeted therapies such as crizotinib increase survival benefit in this patient population. However, further understanding of the disease subtype including patterns of metastasis and pathways of treatment resistance are needed. We describe a 50 year-old-woman diagnosed with stage IV NSCLC, T2N3M1b, ALK fusion positive disease. Although her initial sites of metastasis included the liver and bone, her story is notable for crizotinib resistant growth of a metastatic lesion to her adnexa. This report brings to attention unique mechanisms of metastasis in ALK positive patients.


Adnexa; Anaplastic lymphoma kinase; Metastasis; Non-small cell lung cancer

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center